Mesa Laboratories Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $249.7M+3.6% YoYTTM through 30 Jun 2026
Net Income $4.8MTTM through 30 Jun 2026
Free Cash Flow $52.9MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 63.5% |
| EBITDA Margin | 28.6% |
| Operating Margin | 7.4% |
| Net Margin | 1.9% |
Returns
3.6%ROE
1.6%ROA
2.1%ROIC
Balance Sheet Health
Debt / Equity0.81x
Current Ratio1.79x
Net Debt$122.9M
Cash & Equivalents$30.7M
Quality Metrics
Altman Z-Score2.25
Piotroski F-Score8 / 9
FCF Margin21.2%
Rule of 4025.0
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2026: $249.1M
Diluted EPS$0.85TTMFY2026: $1.21
Dividend
$0.32Per share, FY20260.24%Yield-12.9%5-yr growth
Capital Allocation
R&D Spend$20M
Capex Intensity1.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Sterilization and Disinfection Control | $101.6M | +8.7% | View detailsSDC products are disposable and used on a routine basis, making them less sensitive to general economic conditions. |
| Calibration Solutions | $53.6M | +3.5% | View detailsCS growth was driven by commercial momentum and price increases. |
| Biopharmaceutical Development | $48.6M | -0.2% | View detailsBPD segment was impacted by export-control shipping delays and foreign currency pressures. |
| Clinical Genomics | $45.4M | -3.6% | View detailsCG experienced declines due to weak Chinese market, but grew 9.2% ex-China. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.